Table 2. Effect modification by female reproductive attributes on the associations of selected NOS3 polymorphisms and POAG.
|
SNP |
Genotype |
Overall association between SNP genotypes and POAG |
Menarche <13 years |
Menarche ≥13 years |
Parous 3+ children |
Parous 1–2 children |
No oral contraceptive use |
Oral contraceptive use |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | Number of Cases (MEN-/ MEN+)‡ | RR (95% CI)§ | RR (95% CI)§ | Number of cases (PAR3+/ PAR3-)‡ | RR (95% CI)§ | RR (95% CI)§ | Number of cases (OC-/ OC+)‡ | RR (95% CI)§ | RR (95% CI)§ | ||
| Promoter −786C/T |
TT |
1.00 (ref) |
67/70 |
1.00 |
0.91 (0.59, 1.41) |
46/25 |
1.00 |
1.20 (0.58, 2.49) |
78/59 |
1.00 |
1.60 (1.01, 2.55) |
| |
TC |
1.11 (0.83, 1.47) |
86/80 |
1.24 (0.82, 1.88) |
0.95 (0.62, 1.44) |
56/25 |
0.92(0.54, 1.58) |
1.19(0.60, 2.35) |
95/71 |
1.22 (0.84, 1.78) |
1.62 (1.04, 2.51) |
| |
CC |
1.17 (0.81, 1.70) |
34/28 |
1.33 (0.78, 2.27) |
0.99 (0.57, 1.71) |
25/7 |
1.32 (0.67, 2.63) |
0.46 (0.15, 1.40) |
36/26 |
1.38 (0.85, 2.27) |
1.56 (0.87, 2.81) |
| |
|
|
|
|
p-int=0.54 |
|
|
p-int=0.13 |
|
|
p-int=0.35 |
| Glu298Asp (rs1799983) |
GG |
1.00 (ref) |
79/85 |
1.00 |
1.20 (0.80, 1.81) |
49/34 |
1.00 |
2.03(1.07, 3.83) |
90/74 |
1.00 |
1.35 (0.89, 2.04) |
| |
GT |
0.98 (0.74, 1.31) |
78/65 |
1.50 (0.99, 2.27) |
0.90 (0.59, 1.36) |
56/19 |
1.41 (0.83, 2.41) |
1.18 (0.57, 2.44) |
89/54 |
1.16 (0.80, 1.71) |
1.22 (0.77, 1.93) |
| |
TT |
1.45 (0.98, 2.13) |
30/26 |
2.13 (1.20, 3.77) |
1.45 (0.81, 2.59) |
19/4 |
2.01 (0.96, 4.20) |
0.51 (0.15, 1.78) |
29/27 |
1.32 (0.78, 2.24) |
2.87 (1.50, 5.52) |
| |
|
|
|
|
p-int=0.05 |
|
|
p-int=0.003¶ |
|
|
p-int=0.60 |
|
rs3918188 |
CC |
1.00 (ref) |
100/73 |
1.00 |
0.54 (0.36, 0.81) |
61/19 |
1.00 |
0.66 (0.33, 1.32) |
98/75 |
1.00 |
1.22 (0.80, 1.84) |
| |
CA |
0.79 (0.60, 1.03) |
73/84 |
0.57 (0.39, 0.85) |
0.56 (0.39, 0.83) |
55/30 |
0.91 (0.54, 1.52) |
1.23 (0.67, 2.26) |
91/66 |
0.74 (0.52, 1.06) |
0.99 (0.66, 1.48) |
| |
AA |
0.69 (0.46, 1.05) |
16/25 |
0.31 (0.16, 0.59) |
0.71 (0.40, 1.26) |
11/9 |
0.56 (0.24, 1.33) |
1.42 (0.50, 4.01) |
24/17 |
0.59 (0.34, 1.03) |
0.90 (0.47, 1.73) |
| |
|
|
|
|
p-int=0.0007¶ |
|
|
p-int=0.04 |
|
|
p-int=0.59 |
|
rs7830 |
CC |
1.00 (ref) |
88/84 |
1.00 |
0.83 (0.56, 1.23) |
54/29 |
1.00 |
1.36 (0.70, 2.61) |
101/71 |
1.00 |
1.22 (0.80, 1.86) |
| |
CA |
0.75 (0.57, 0.98) |
75/71 |
0.76 (0.51, 1.14) |
0.58 (0.39, 0.86) |
52/22 |
0.73 (0.45, 1.21) |
0.75 (0.39, 1.45) |
79/67 |
0.69 (0.48, 0.99) |
0.99 (0.66, 1.49) |
| |
AA |
1.16 (0.78, 1.73) |
27/28 |
1.04 (0.58, 1.86) |
1.09 (0.62, 1.92) |
21/7 |
1.23 (0.59, 2.56) |
0.93 (0.32, 2.68) |
34/21 |
1.16 (0.70, 1.93) |
1.44 (0.75, 2.75) |
| p-int=0.82 | p-int=0.29 | p-int=0.86 |
Abbreviations: POAG: primary-open angle glaucoma; OC+: oral contraceptive use, OC-: never used OC; PAR3+: parous with 3 or more children, PAR3-: parous with 1 or 2 children; MEN-: menarche<13, MEN+: menarche≥13. ‡The number of cases may not add up to 374 because those with missing data were not included in analyses. §Adjusted for family history of glaucoma, hypertension, diabetes, parity, oral contraceptive use, smoking status, body mass index, age at menopause, postmenopausal hormone use, alcohol intake, caffeine intake, physical activity. Statistically significant with multiple testing correction (False Discovery Rate).